I am a
Home I AM A Search Login

Papers of the Week

2020 Nov 04

Clin Cancer Res

OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors.


Gutierrez M, Moreno V, Heinhuis KM, Olszanski AJ, Spreafico A, Ong M, Chu QS, Carvajal RD, Trigo J, Ochoa de Olza M, Provencio M, De Vos F, de Braud F, Leong S, Lathers D, Wang R, Ravindran P, Feng Y, Aanur P, Melero I
Clin Cancer Res. 2020 Nov 04.
PMID: 33148673.


This phase 1/2a study (NCT02737475) evaluated the safety and activity of BMS-986178, a fully human OX40 agonist immunoglobulin G1 monoclonal antibody, ± nivolumab and/or ipilimumab in patients with advanced solid tumors.